Free Trial
NASDAQ:CGON

CG Oncology (CGON) Stock Price, News & Analysis

CG Oncology logo
$33.47 +1.13 (+3.49%)
(As of 05:16 PM ET)

About CG Oncology Stock (NASDAQ:CGON)

Key Stats

Today's Range
$32.26
$33.86
50-Day Range
$32.24
$39.94
52-Week Range
$25.77
$50.23
Volume
404,075 shs
Average Volume
645,810 shs
Market Capitalization
$2.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.88
Consensus Rating
Buy

Company Overview

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

CG Oncology Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
64th Percentile Overall Score

CGON MarketRank™: 

CG Oncology scored higher than 64% of companies evaluated by MarketBeat, and ranked 397th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CG Oncology has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CG Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CG Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for CG Oncology are expected to decrease in the coming year, from ($1.31) to ($1.94) per share.

  • Price to Book Value per Share Ratio

    CG Oncology has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about CG Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    13.92% of the float of CG Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    CG Oncology has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in CG Oncology has recently decreased by 6.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    CG Oncology does not currently pay a dividend.

  • Dividend Growth

    CG Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.92% of the float of CG Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    CG Oncology has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in CG Oncology has recently decreased by 6.04%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    CG Oncology has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for CG Oncology this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for CGON on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,000,089.00 in company stock.

  • Percentage Held by Institutions

    Only 26.56% of the stock of CG Oncology is held by institutions.

  • Read more about CG Oncology's insider trading history.
Receive CGON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter.

CGON Stock News Headlines

Test tubes on blue background — Photo
Discover the 3 Best-Performing Biotech IPO Stocks of 2024 (CGON)
Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.
A “Thank You Gift” From Pres. Trump - Genius
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
FY2024 EPS Estimates for CG Oncology Increased by Analyst
CG Oncology (NASDAQ:CGON) Earns "Buy" Rating from HC Wainwright
Analysts Set CG Oncology, Inc. (NASDAQ:CGON) Price Target at $63.88
See More Headlines

CGON Stock Analysis - Frequently Asked Questions

CG Oncology's stock was trading at $37.17 on January 1st, 2024. Since then, CGON stock has decreased by 10.0% and is now trading at $33.44.
View the best growth stocks for 2024 here
.

CG Oncology, Inc. (NASDAQ:CGON) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. The business had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.30 million. CG Oncology had a negative trailing twelve-month return on equity of 18.97% and a negative net margin of 10,642.98%.

CG Oncology (CGON) raised $380 million in an initial public offering (IPO) on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share.

Top institutional investors of CG Oncology include Braidwell LP (4.73%), State Street Corp (2.54%), Janus Henderson Group PLC (2.28%) and Geode Capital Management LLC (1.61%). Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche and Vijay Kasturi.
View institutional ownership trends
.

Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA).

Company Calendar

Last Earnings
11/12/2024
Today
11/22/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/25/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CGON
Previous Symbol
NASDAQ:CGON
Fax
N/A
Employees
61
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$63.88
High Stock Price Target
$75.00
Low Stock Price Target
$50.00
Potential Upside/Downside
+96.8%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

Net Income
$-48,610,000.00
Net Margins
-10,642.98%
Pretax Margin
-10,642.98%

Debt

Sales & Book Value

Annual Sales
$200,000.00
Price / Sales
10,976.35
Book Value
$7.94 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.20 billion
Optionable
Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CGON) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners